FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917383926> ?p ?o ?g. }

• W2917383926 endingPage "2885" @default.
• W2917383926 startingPage "2885" @default.
• W2917383926 abstract "Abstract Background/Objective: Marginal zone B-cell lymphomas (MZL) represent a heterogeneous group of indolent lymphomas, comprising of MALT lymphomas, nodal MZL and splenic MZL. Currently, there has been no widely accepted prognostic indices for these lymphomas. Recently, the International Extranodal Lymphoma Study Group (IELSG) developed a novel simplified MALT prognostic index (MALT-IPI)1, which was subsequently validated by a western cohort of MALT cases. To date, there has not been an assessment of the applicability of this score in other subtypes of MZL or in the Asian population, where geographic and ethnical differences may influence disease epidemiology and outcomes. Our study aimed to 1) Evaluate clinical characteristics and survival outcomes for a large cohort of Southeast Asian patients with MZL who were diagnosed between 1993 - 2018 and ii) Assess the prognostic significance of the MALT-IPI for this patient cohort. Patients and Methods: We retrospectively studied 286 consecutive patients with newly diagnosed MZL treated between 1993 to 2016 at 2 tertiary cancer centres in Singapore. Data on clinical parameters, treatments, response, and survival were evaluated. In addition, all patients with available data were classified according to the MALT-IPI (N =236, including MALT lymphomas N= 190 and nodal/splenic MZL, N= 46) and the prognostic significance of this score was evaluated. Results: Among 286 patients with MZL, 230 patients (80%) had MALT lymphomas, 35 (12%) had nodal MZL and 21 (7%) had splenic MZL. The median age was 60 years (range 15- 94), 49% of the patients were male and 183 patients (64%) had Stage I-II disease. The majority of the patients were managed by either radiotherapy (N= 77, 27%), chemo and/or immunotherapy (N= 76, 27%), watchful waiting (N-= 46, 16%) or antibiotics (N= 33, 11.5%).With a median follow-up of 46 mths (range 1 - 266 mths) for all patients, the 5 yr-PFS for the cohort was 59.8 %. Progression free survival was significantly better for the MALT subgroups compared to the nodal and splenic MZL subgroups ( 5 yr PFS of 63.6 vs 49.7 % vs 30.5 % respectively, p=0.002). The 5-yr OS was excellent at 86.7% and there were no differences between the MALT, nodal MZL and splenic MZL cohorts (5-yr PFS 87.1 vs 85.3% vs 86.4, p=0.667). Age, ECOG status and elevated LDH were prognostic for PFS on univariate analysis but none has significant impact on multivariate analysis. No other baseline clinical characteristic (including gender and disease stage) was significantly associated with PFS. Age and ECOG was significantly associated with OS on both univariate and multivariate analysis. In our cohort, the MALT-IPI was a significant prognostic marker with ability to discriminate different prognostic groups with respect to PFS and OS. The 5-year progression-free survival rate for patients who had MALT-IPI scores of 0, 1 or 2-3 were 78%, 58% and 42%, respectively (p<0.001). The 5-year OS rates for patients who had MALT-IPI scores of 0, 1 or 2-3 were 98% , 89% and 68% respectively (p <0.001). Table 1 and Figure 1A and B summarises the survival endpoints (PFS and OS) according to the MALT-IPI in our patient cohort. Conclusion We demonstrated the prognostic applicability of the MALT-IPI to identify patients at risks of progression or death, in a large cohort of Asian patients with MZL. Patients with high risk MALT-IPI appear to be associated with poor outcomes and may be candidates for novel treatment approaches. Disclosures Jeyasekharan: AstraZeneca: Other: Collaboration; Merck Sharp & Dohme: Honoraria; PerkinElmer: Other: Collaboration; Janssen: Research Funding. Goh:Johnson & Johnson: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Sanofi-Aventis: Consultancy, Honoraria; Bristol-Myers-Squibb: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria." @default.
• W2917383926 created "2019-03-02" @default.
• W2917383926 creator A5001985176 @default.
• W2917383926 creator A5008789298 @default.
• W2917383926 creator A5009336240 @default.
• W2917383926 creator A5009443310 @default.
• W2917383926 creator A5012337680 @default.
• W2917383926 creator A5020230599 @default.
• W2917383926 creator A5020283356 @default.
• W2917383926 creator A5028165330 @default.
• W2917383926 creator A5032292277 @default.
• W2917383926 creator A5036527685 @default.
• W2917383926 creator A5038667383 @default.
• W2917383926 creator A5042375742 @default.
• W2917383926 creator A5046526105 @default.
• W2917383926 creator A5048089232 @default.
• W2917383926 creator A5063931756 @default.
• W2917383926 creator A5063963087 @default.
• W2917383926 creator A5071011466 @default.
• W2917383926 creator A5071505934 @default.
• W2917383926 creator A5080656059 @default.
• W2917383926 creator A5085639508 @default.
• W2917383926 creator A5091237771 @default.
• W2917383926 date "2018-11-29" @default.
• W2917383926 modified "2023-10-14" @default.
• W2917383926 title "Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases" @default.
• W2917383926 doi "https://doi.org/10.1182/blood-2018-99-118364" @default.
• W2917383926 hasPublicationYear "2018" @default.
• W2917383926 type Work @default.
• W2917383926 sameAs 2917383926 @default.
• W2917383926 citedByCount "0" @default.
• W2917383926 crossrefType "journal-article" @default.
• W2917383926 hasAuthorship W2917383926A5001985176 @default.
• W2917383926 hasAuthorship W2917383926A5008789298 @default.
• W2917383926 hasAuthorship W2917383926A5009336240 @default.
• W2917383926 hasAuthorship W2917383926A5009443310 @default.
• W2917383926 hasAuthorship W2917383926A5012337680 @default.
• W2917383926 hasAuthorship W2917383926A5020230599 @default.
• W2917383926 hasAuthorship W2917383926A5020283356 @default.
• W2917383926 hasAuthorship W2917383926A5028165330 @default.
• W2917383926 hasAuthorship W2917383926A5032292277 @default.
• W2917383926 hasAuthorship W2917383926A5036527685 @default.
• W2917383926 hasAuthorship W2917383926A5038667383 @default.
• W2917383926 hasAuthorship W2917383926A5042375742 @default.
• W2917383926 hasAuthorship W2917383926A5046526105 @default.
• W2917383926 hasAuthorship W2917383926A5048089232 @default.
• W2917383926 hasAuthorship W2917383926A5063931756 @default.
• W2917383926 hasAuthorship W2917383926A5063963087 @default.
• W2917383926 hasAuthorship W2917383926A5071011466 @default.
• W2917383926 hasAuthorship W2917383926A5071505934 @default.
• W2917383926 hasAuthorship W2917383926A5080656059 @default.
• W2917383926 hasAuthorship W2917383926A5085639508 @default.
• W2917383926 hasAuthorship W2917383926A5091237771 @default.
• W2917383926 hasBestOaLocation W29173839261 @default.
• W2917383926 hasConcept C126322002 @default.
• W2917383926 hasConcept C142724271 @default.
• W2917383926 hasConcept C144301174 @default.
• W2917383926 hasConcept C159654299 @default.
• W2917383926 hasConcept C203014093 @default.
• W2917383926 hasConcept C2778453870 @default.
• W2917383926 hasConcept C2778476033 @default.
• W2917383926 hasConcept C2778559949 @default.
• W2917383926 hasConcept C2778563104 @default.
• W2917383926 hasConcept C2779338263 @default.
• W2917383926 hasConcept C2779526237 @default.
• W2917383926 hasConcept C2779714933 @default.
• W2917383926 hasConcept C2779851268 @default.
• W2917383926 hasConcept C2779921676 @default.
• W2917383926 hasConcept C2908647359 @default.
• W2917383926 hasConcept C38180746 @default.
• W2917383926 hasConcept C71924100 @default.
• W2917383926 hasConcept C72563966 @default.
• W2917383926 hasConcept C90924648 @default.
• W2917383926 hasConcept C99454951 @default.
• W2917383926 hasConceptScore W2917383926C126322002 @default.
• W2917383926 hasConceptScore W2917383926C142724271 @default.
• W2917383926 hasConceptScore W2917383926C144301174 @default.
• W2917383926 hasConceptScore W2917383926C159654299 @default.
• W2917383926 hasConceptScore W2917383926C203014093 @default.
• W2917383926 hasConceptScore W2917383926C2778453870 @default.
• W2917383926 hasConceptScore W2917383926C2778476033 @default.
• W2917383926 hasConceptScore W2917383926C2778559949 @default.
• W2917383926 hasConceptScore W2917383926C2778563104 @default.
• W2917383926 hasConceptScore W2917383926C2779338263 @default.
• W2917383926 hasConceptScore W2917383926C2779526237 @default.
• W2917383926 hasConceptScore W2917383926C2779714933 @default.
• W2917383926 hasConceptScore W2917383926C2779851268 @default.
• W2917383926 hasConceptScore W2917383926C2779921676 @default.
• W2917383926 hasConceptScore W2917383926C2908647359 @default.
• W2917383926 hasConceptScore W2917383926C38180746 @default.
• W2917383926 hasConceptScore W2917383926C71924100 @default.
• W2917383926 hasConceptScore W2917383926C72563966 @default.
• W2917383926 hasConceptScore W2917383926C90924648 @default.
• W2917383926 hasConceptScore W2917383926C99454951 @default.
• W2917383926 hasIssue "Supplement 1" @default.
• W2917383926 hasLocation W29173839261 @default.
• W2917383926 hasOpenAccess W2917383926 @default.
• W2917383926 hasPrimaryLocation W29173839261 @default.

• next